[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.425 1.35 1.50 1.575 1.3675 1.43 8,695,919 11:13:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.2 -1.4 -0.2 - 8

Nuformix Share Discussion Threads

Showing 7476 to 7496 of 7825 messages
Chat Pages: Latest  301  300  299  298  297  296  295  294  293  292  291  290  Older
DateSubjectAuthorDiscuss
21/4/2021
08:58
I thought you had 'sticky fingers' Georgeo, especially after all those posts you made about the glowing prospects of the company.
for fx sake
21/4/2021
08:28
Held long until the recent selling when it dropped, now back in again regretfully at a higher premium should stay and hold on.
georgeo1
21/4/2021
08:18
Surely eventually NFX has to bounce?
billthebank
20/4/2021
16:29
Is someone shuffling the pack? Large turnover in shares traded today
carlisle44
20/4/2021
13:13
No Royalalbert but the share price being so low s/he must be almost out imho.
maytrees
20/4/2021
13:12
Maytrees any idea how many the seller may have left.
royalalbert
20/4/2021
13:03
Odd though with so many buys that the share price is not rising again. Still with FTSE100 down c.80 points one can be thankful for small NFX gain Edit: further small gain as I typed.
maytrees
09/4/2021
20:09
And don't get excited by Covid links, NFX have said this is not a priority.
soupdragon55
09/4/2021
20:08
NXP004 won't go to Oxilio, the company has said so. It tells you what the plan is in the Allenby research note you posted a link to.
soupdragon55
09/4/2021
18:54
SNG001 NXP004 OXL001 maybe OXL004
georgeo1
09/4/2021
18:43
COVID-19East Texas researcher receives grant to continue work on novel drug for COVID-19-related lung diseaseUT Health Science Center in Tyler (Source: Blake Holland/KLTV)By UT Health Science Center at Tyler | April 1, 2021 at 7:01 AM CDT - Updated April 1 at 8:28 AMTYLER, Texas (KLTV) - The University of Texas Health Science Center at Tyler (UTHSCT) researcher Dr. Sreerama Shetty, a cellular and molecular biology professor, has received a two-year Department of Defense (DoD) grant for nearly $300,000 to continue research on a novel intervention therapy he and his research team have developed for COVID-19-related lung disease."Our research has a strong potential of yielding a new, safe, convenient and effective intervention for patients with COVID-19 due to infection caused by coronavirus 2 (CoV-2)," Shetty said. Patients with acute lung injury (ALI) from COVID-19 often die due to acute lung inflammation that can lead to alveolar damage and organ failure. The CoV-2 targets ACE-2 proteins lining the surface of human cells, including the alveolar cells in the lungs, causing ALI and alveolar epithelial cell death and lung scarring, making a lack of air exchange life threatening.Shetty's research identified a specific peptide, called LTI-03 (also called CSP7), that inhibits alveolar epithelial cell lung injury, including ALI due to sepsis."LTI-03 is well tolerated, can be delivered systemically or via the airway in liquid formulation or micronized dry powder form," Shetty said. "We believe LTI-03 can mitigate ALI associated with COVID-19. Our research will test the efficacy of systemically and airway-delivered LTI-03 against alveolar epithelial cell damage and acute lung injury."Shetty's research will determine whether systemically delivered LTI-03 improves overall survival by inhibiting ALI due to CoV-2 infection and will determine whether better efficacy is achieved by airway inhalation using standard lung function, CT imaging, blood oxygenation, lung viral load, biochemical and histological markers and survival endpoints."Our grant proposal caters to the aggregate strengths of the team in drug discovery, formulation, airway delivery and virology," Shetty said.LTI-03 could be a potential treatment for chronic lung disease called idiopathic pulmonary fibrosis (IPF) that causes progressive lung scarring primarily in adults age 65 and older. With no known cure, fatality is generally three to five years following diagnosis. LTI-03 administered as an inhalant is entering clinical safety trials in Ireland and could cause a worldwide paradigm shift in the treatment of lung fibrosis."If the clinical trials are successful, LTI-03 as an inhalant could become the signature career work of my lifetime," Shetty said.Initial evidence suggests that LTI-03 reverses lung fibrosis in multiple preclinical models, including human IPF tissues, reduces fluid buildup in the lungs that causes life-threatening pneumonia and restores the survival of damaged lung lining cells. IPF causes about 40,000 deaths annually.Antifibrotic drugs approved in 2014 to treat IPF only decelerated the progression of fibrosis, buying patients more time, but LTI-03 as an inhalation therapy holds promise to return patients to healthier lung function by sustaining the survival of damaged lung lining cells and targeting a different cellular signaling pathway than previous pharmaceutical approaches.UTHSCT attracts some of the top researchers from around the world to its 150,000-square-foot research facility in Tyler, Texas, where new medications, protocols and cures are developed. Researchers have earned nearly $300 million in grant-funded research to offer hope to patients in need.Copyright 2021 KLTV. All rights reserved.
georgeo1
09/4/2021
13:31
It's holding up rather well today despite the dumpers' best efforts.
for fx sake
09/4/2021
12:20
Just waiting for a tick up for a blue day to start off next week with a bang.
georgeo1
09/4/2021
11:08
http://www.allenbycapital.com/research_1168_68002803.pdf
georgeo1
09/4/2021
11:08
NEWSFLOWOver the next 12-18 months there are a number of possible events on the horizon:– Initiation of the feasibility studies on NXP002 in Q2 2021– OutcomedecisiononOxiliooptiononNXP001.– News on patent filing outcomes, strategic path and partnering for NXP004 in oncology.– Outcome of Innovate UK Grant Application for NXP002 in Q1 2021.– Potential completion (subject to funding) of Phase I ready package for NXP002by H1 2022.– Partneringnewsacrossthepipeline.– Corporate: FY results 12 months ended 31 March 2021 – date estimated July/August.
georgeo1
09/4/2021
11:06
NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in upfront and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset: from feasibility up to the full Phase I ready GLP package, assuming successful outcomes and based on recent precedent. We illustrate a range of deal metrics in IPF to support our assumptions. Industry precedent shows that once a robust patent position is built, even early stage IPF assets are attracting significant deals in the indication. While pipelines are filling out, the novel approach, acute need and the inhaled route of administration are key factors that can differentiate NXP002. This from recent Allenby Capital report.
georgeo1
09/4/2021
11:03
Yes it has 22 March 2021 Nuformix plc ("Nuformix", the "Company" or the "Group") NXP001 (Oncology) - Exercise of Option by Oxilio London, UK - 22 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that Oxilio Ltd ("Oxilio") has exercised its option to acquire a licence for NXP001 (a proprietary new form of aprepitant) for oncology indications. · On 23 September 2020, Nuformix granted an exclusive option to Oxilio, a private pharmaceutical development company, to license NXP001 globally for oncology indications. This triggered the first upfront payment and the option period ran until 23 March 2021 · Nuformix and Oxilio will now work together to finalise a global licensing agreement for NXP001. Once this has been agreed, this will trigger a second undisclosed upfront payment, payable to Nuformix. Under this agreement, Nuformix will license its patent estate and know-how on NXP001 in return for development milestone payments and a royalty on any future net sales, capped at £2m per annum
spurs90
09/4/2021
10:59
Has a global licensing agreement been reached with Oxilio, which expired in March?It was six months since September last year, must be waiting for that news at least.
georgeo1
09/4/2021
10:43
From Oxilio website,Our approach to drug repurposing sets us apart from most other repurposing companies. We aim to repurpose an existing drug through optimisation of the formulation, dose and dosing regimen in order to maximise its efficacy in the new indication. Our OXL001 clinical trial programme is being designed to satisfy all aspects of drug safety and efficacy associated with optimal formulation, dose and dosing regimen of OXL001 in the treatment of cancer. The programme is informed by our advanced formulation and modelling/simulation work. We aim to take our first formulation of OXL001 into the clinic later in 2021.
georgeo1
09/4/2021
08:55
Fundraise coming lol! They only got the money from the recent one last week.
soupdragon55
09/4/2021
00:29
Holding RNS, it's a sell. Another fundraise coming i suppose
letmepass
Chat Pages: Latest  301  300  299  298  297  296  295  294  293  292  291  290  Older
ADVFN Advertorial
Your Recent History
LSE
NFX
Nuformix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211022 14:19:50